U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542548) titled 'D-Cycloserine for Serine Palmitoyltransferase Inhibition' on March 04.

Brief Summary: The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia

Study Start Date: July 10, 2024

Study Type: INTERVENTIONAL

Condition: Hereditary Spastic Paraplegia

Intervention: DRUG: D-cycloserine

Pyridoxine also prescribed to help prevent neurologic adverse events related to D-Cycloserine.

Recruitment Status: COMPLETED

Sponsor: Massachusetts General Hospital

Information provided by (Responsible Party): Florian Eichler, Massachusetts General Hospital

D...